REGN REGENERON PHARMACEUTICALS

2026Q2 · CUSIP 75886F107 · Sector: Healthcare & Biotech

Normal

Fund flows are within the usual range

Funds that own it

1,296

Institutions that reported holding it to the SEC

Net decrease in holders

Last quarter 1,391 → now 1,296

How unusual is that

Bottom 20%

Stronger than only 0.9% of US stocks

What the filings say, in one paragraph

1,296 funds held REGN at the end of 2026Q2, down 95 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $15.5B(YoY +9.3%), the P/E is 21.1x, return on equity is 13.7%. REGN has had 32 buying rushes in its history, and the price moved +1.1% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

What happened after each past buying rush 32 times in its history

Quarter of the rush	How unusual then	Price, next 3 months	Price, next 6 months
2025Q4	Top 5%	-2.7%	-16.7%
2025Q3	Top 10%	+8.5%	+11.2%
2024Q3	Top 5%	-5.8%	-8.0%
2024Q2	Top 20%	-11.2%	-33.6%
2024Q1	Top 10%	+4.3%	+21.8%
2023Q4	Top 5%	+0.3%	+3.6%
2023Q3	Top 20%	+15.2%	+18.9%
2023Q1	Top 5%	-4.2%	+6.3%
2022Q4	Top 5%	+12.2%	+1.5%
2022Q3	Top 10%	-1.2%	+1.8%
2022Q1	Top 20%	-9.8%	-5.2%
2021Q4	Top 10%	+10.7%	+4.5%
2021Q3	Top 5%	-2.3%	-2.4%
2021Q2	Top 5%	-10.2%	+1.1%
2020Q2	Top 1% in the market	-9.8%	-8.7%
2020Q1	Top 1% in the market	+8.7%	+10.8%
2019Q4	Top 10%	+22.2%	+44.3%
2019Q1	Top 5%	+4.4%	-2.7%
2018Q4	Top 20%	-4.0%	-28.1%
2018Q3	Top 10%	+14.9%	+21.2%
2017Q4	Top 20%	-1.1%	-9.1%
2017Q3	Top 20%	-3.0%	-18.2%
2017Q2	Top 10%	-1.3%	-17.9%
2016Q4	Top 20%	+2.7%	+22.6%
2015Q4	Top 20%	+4.6%	+0.8%
2015Q3	Top 5%	-13.3%	-32.6%
2015Q2	Top 5%	-19.4%	-4.8%
2014Q4	Top 10%	+3.2%	+20.2%
2014Q3	Top 5%	+2.6%	+6.7%
2014Q1	Top 20%	+2.1%	+15.7%
2013Q4	Top 20%	-5.3%	-8.8%
2013Q3	Top 5%	-1.0%	+19.4%

Show all 32 events

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾

Of them, large funds

343

Change in large funds

+20

Total value they hold

$57.8B

Funds buying for the first time

122

Funds that sold out entirely

217

Price change that quarter

+35.5%

Funds holding puts (bearish)

Funds holding calls (bullish)

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)

21.1

EPS (TTM)

$40.38

EPS YoY

+1.6%

Revenue (TTM)

$15.5B

Revenue YoY

+9.3%

Net margin

27.9%

ROE

13.7%

Debt ratio

24.0%

FCF (TTM)

$3.8B

Dividend (TTM)

$3.64

Quarterly Revenue & EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close around day 47 after quarter-end ÷ TTM EPS then; this is a consistent valuation date, not the company’s actual filing date; loss quarters hidden

Quarterly free cash flow

Latest quarter $848M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.